Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: A 6-month, multicenter, cohort study

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 11, 2009, Pages 1705-1711

  Rossi, Gemma C M ^a,b   Pasinetti, Gian Maria ^c   Bracchino, Maurizio ^d   Bucarelli, Massimo ^d   Franchin, Stefano ^e   Cerqueti, Piera ^f   Bellini, Rosa ^g   Caravati, Cleofe ^e   Celesia, Laura ^h   Clemente, Antonella ⁱ   Tinelli, Carmine ^j  

^a Pavia System   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Istituto Beato Palazzolo   (Italy)

^d AO Lecco   (Italy)

^e AO Lecco ^*

^f Ospedale Civile Acqui Terme   (Italy)

^g AO Bolognini   (Italy)

^h ASL Biella   (Italy)

ⁱ Policlinico di Monza   (Italy)

^j FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

Efficacy; Switch; TBUT; Tolerability; Travoprost 0.004 timolol 0.5 fixed combination

Indexed keywords

LATANOPROST; TIMOLOL; TIMOLOL PLUS TRAVOPROST;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BURNING SENSATION; COHORT ANALYSIS; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PERIOCULAR PIGMENTATION; PIGMENT DISORDER; PRURITUS; TEAR FILM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 68149157192     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903061283     Document Type: Article

References (30)

1. Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: Meta-analysis of randomised controlled trials. BMJ 2005;331:134-136 (Pubitemid 41003170)
2. Bengtsson B, Heijl A. A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J Glaucoma 2005;14:135-138 (Pubitemid 40389182)
3. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-440
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-713
5. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-720
6. Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
7. Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15:102-106 (Pubitemid 38457128)
8. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982;93:232-237
9. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol 2000;11:112-115 (Pubitemid 30164031)
10. Higginbotham EJ, Feldman R, Stiles M, et al. The Fixed Combination Investigative Group. Latanoprost and timolol combination therapy versus monotherapy: One-year randomized trial. Arch Ophthalmol 2002;120:915-922
11. Denis P, Andrew R, Wells D, et al. A comparison of morning and evening instillation of a combination Travoprost 0.004%/Timolol 0.5% ophthalmic solution. Eur J Ophthalmol 2006;16:407-415 (Pubitemid 44049283)
12. Hughes BA, Bacharach J, Craven ER, et al. A three month, multicenter, double-masked study of the safety and efficacy of Travoprost 0.004%/Timolol 0.5% ophthalmic solution compared to Travoprost 0.004% ophthalmic solution and Timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 2005;14:392-399 (Pubitemid 41383334)
13. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of Travoprost 0.004%/Timolol 0.5% ophthalmic solution once-daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005;140:242-250
14. Hommer A. For the Ganfort Investigators Group. I. A double- masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:53-62
15. Xiong C, Chen D, Liu J, et al. A rabbit model induced by topical medication of a preservative Benzalkonium Chloride. Invest Ophthalmol Vis Sci 2008;49:1850-1856
16. Rossi GCM, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol 2009;19:572-579
17. EGS. Terminology and guidelines for glaucoma. Savona: Dogma editor, 3rd edition, 2008
18. Diestelhorst M, Larsson LI. European Latanoprost Fixed Combination Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 2004;88:199-203 (Pubitemid 38142086)
19. Hamacher T, Schinzel M, Scholzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0,005%/timolol maleate 0,5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol 2004;88:1295-1298 (Pubitemid 39312975)
20. Denis P, Lafuma A, Jeanbat V, et al. Intraocular pressure control with Latanoprost/Timolol and Travoprost/Timolol fixed combinations: a retrospective, multicentre, cross-sectional study. Clin Drug Investig 2008;28:767-776
21. Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily Travoprost 0.004%/Timolol 0.5% to once-daily Latanoprost 0.005%/Timolol 0.5% in patients with open angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:183-190 (Pubitemid 46918103)
22. Schimier JK, Halpern MT, Covert DW, Robin AL. Travoprost versus Latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. Curr Med Res Opin 2006;22:1737-1743
23. Arend KO, Baber T. Observational study results in glaucoma patients undergoing a regimen replacement to fixed combination Travoprost 0,004%/Timolol 0,5% in Germany. J Ocul Pharmacol Ther 2008;24:414-420
24. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of Travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1-7 (Pubitemid 41008083)
25. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of Travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001;17:421-432 (Pubitemid 33116119)
26. Baudouin C, de Lunardo C. Short term comparative study of topical 2% cartelol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998;82:39-42 (Pubitemid 28176961)
27. Guenoun JM, Badouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, Travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:2444-2450
28. Rolando M, Refojo MF. Tear evaporatimeter for measuring water evaporation rate from the tear film under controlled conditions in humans. Exp Eye Res 1983;36:25-33 (Pubitemid 13188395)
29. Zimmerman TJ, Stewart WC. For Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther 2003;19:405-415
30. Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol 2001;131:798-799